Simultaneous Inhibition of EGFR, VEGFR and PDGFR Signaling Combined with Gemcitabine Produces Therapy of Human Pancreatic Carcinoma and Prolongs Survival in an Orthotopic Nude Mouse Model

Although gemcitabine has been approved as the first-line chemotherapeutic reagent for pancreatic cancer, its response rate is low and average survival duration is still only marginal. Because epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), and platelet-d...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Yokoi, Kenji, Sasaki, Takamitsu, Bucana, Corazon D., Fan, Dominic, Baker, Cheryl H., Kitadai, Yasuhiko, Kuwai, Toshio, Abbruzzese, James L., Fidler, Isaiah J.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2005
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC1456803/
https://ncbi.nlm.nih.gov/pubmed/16288027
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-05-1698
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים